BPC
ARCT icon

Banque Pictet & Cie’s Arcturus Therapeutics ARCT Stock Holding History

Banque Pictet & Cie’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,000
Closed -$464K – 326
2024
Q3 		$464K Hold
20,000
– – ﹤0.01% 267
2024
Q2 		$487K Hold
20,000
– – ﹤0.01% 261
2024
Q1 		$675K Hold
20,000
– – 0.01% 258
2023
Q4 		$631K Hold
20,000
– – 0.01% 265
2023
Q3 		$511K Hold
20,000
– – 0.01% 336
2023
Q2 		$574K Hold
20,000
– – 0.01% 373
2023
Q1 		$479K Hold
20,000
– – ﹤0.01% 468
2022
Q4 		$339K Hold
20,000
– – ﹤0.01% 551
2022
Q3 		$296K Hold
20,000
– – ﹤0.01% 568
2022
Q2 		$315K Hold
20,000
– – ﹤0.01% 572
2022
Q1 		$539K Hold
20,000
– – ﹤0.01% 524
2021
Q4 		$740K Hold
20,000
– – 0.01% 490
2021
Q3 		$956K Hold
20,000
– – 0.01% 261
2021
Q2 		$677K Hold
20,000
– – 0.01% 283
2021
Q1 		$826K Hold
20,000
– – 0.01% 266
2020
Q4 		$868K Buy
+20,000
New +$1.35M 0.01% 240

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Banque Pictet & Cie's ARCT Position: Q4 2024 in Review

Banque Pictet & Cie sold out of Arcturus Therapeutics (ARCT) in Q4 2024, closing a stake of 20,000 shares — an estimated $464K sold.

Banque Pictet & Cie first reported a position in ARCT in Q4 2020 and held it in 16 quarters. The position peaked at $956K in Q3 2021. 147 funds tracked by Wall St. Rank hold ARCT as of Q4 2024.

  • Banque Pictet & Cie reported no remaining Arcturus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Banque Pictet & Cie sold 20,000 Arcturus Therapeutics shares in Q4 2024, an estimated $464K.
  • Banque Pictet & Cie first reported a position in Arcturus Therapeutics in Q4 2020 and held it in 16 quarters.
  • Banque Pictet & Cie's Arcturus Therapeutics position peaked at $956K in Q3 2021.
  • 147 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2024.

Based on Banque Pictet & Cie's 13F filing for Q4 2024, filed 30 Jan 2025.